Related Experiment Video
Updated: Feb 5, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
Antibody drug conjugates: Progress, pitfalls, and promises
Anubhab Mukherjee1,2, Ariana K Waters1,2, Ivan Babic2
1Drug Discovery and Nanomedicine Research Program, CA-90404, USA.
Abstract:
Antibody drug conjugates (ADCs) represent a promising and an efficient strategy for targeted cancer therapy. Comprised of a monoclonal antibody, a cytotoxic drug, and a linker, ADCs offer tumor selectively, reduced toxicity, and improved stability in systemic circulation. Recent approvals of two ADCs have led to a resurgence in ADC research, with more than 60 ADCs under various stages of clinical development. The therapeutic success of future ADCs is dependent on adherence to key requirements of their design and careful selection of the target antigen on cancer cells. Here we review the main components in the design of antibody drug conjugates, improvements made, and lessons learned over two decades of research, as well as the future of third generation ADCs.
Insights
Antibody drug conjugates (ADCs) offer targeted cancer therapy by combining antibodies with drugs. Research is advancing, focusing on design and antigen selection for future ADC success.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Antibody drug conjugates (ADCs) are an effective targeted cancer therapy.
- ADCs comprise a monoclonal antibody, a cytotoxic drug, and a linker for tumor selectivity.
- Recent approvals have spurred significant research, with over 60 ADCs in clinical development.
Purpose of the Study:
- To review the key components in designing antibody drug conjugates.
- To discuss improvements and lessons learned in ADC research over two decades.
- To explore the future of third-generation ADCs.
Main Methods:
- Literature review of antibody drug conjugate research.
- Analysis of ADC design principles and components.
- Examination of historical data and future trends in ADC development.
Main Results:
- ADCs provide targeted delivery, reduced toxicity, and enhanced stability.
- Successful ADC design relies on specific antigen selection and optimized components.
- Ongoing research focuses on overcoming challenges and advancing ADC technology.
Conclusions:
- Antibody drug conjugates are a vital tool in targeted cancer therapy.
- Continued research and careful design are crucial for the success of future ADCs.
- The evolution of ADCs, including third-generation therapies, promises improved cancer treatment outcomes.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
09:15Optimization, Design and Avoiding Pitfalls in Manual Multiplex Fluorescent Immunohistochemistry
Published on: July 26, 2019
Related Concept Videos
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Conjugated Proteins
Conjugation
Mechanism of Conjugation
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...